Amgen Financial Results: Q1 2026 Performance Breakdown
Amgen financial results for the first quarter of 2026 reveal strong performance. Revenues increased 6% to $8.6 billion. Product sales grew 4%. Volume drove most of this growth. The company generated $1.5 billion in free cash flow (Amgen, 2026).
Key Performance Highlights
- Sixteen products achieved double-digit growth.
- Repatha sales rose 34% to $876 million.
- EVENITY sales increased 27% to $562 million.
- UPLIZNA sales surged 188% to $262 million.
- IMDELLTRA sales jumped 219% to $258 million.
- Enbrel sales dropped 37% to $320 million.
- Prolia sales declined 34% to $727 million.
- Non-GAAP earnings per share rose 5% to $5.15.
- The operating margin reached 45.3%.
Pipeline Progress
Amgen advanced several programs. MariTide entered multiple Phase 3 studies. These cover weight management and heart conditions. TEPEZZA showed positive results in a new form. UPLIZNA gained approval in Europe.
Amgen financial results indicate capacity for future investments. Full-year revenue guidance is $37.1 billion to $38.5 billion. This funds research in obesity and oncology. It may also support new health economics data. Learn more in the company’s official press release on Amgen financial results.
Frequently Asked Questions
What drove Amgen’s product sales growth?
Volume growth of 9% across the portfolio led to a 4% rise in product sales.
How is Amgen advancing its pipeline?
The company runs Phase 3 studies for MariTide. It also has new data for TEPEZZA. UPLIZNA received European approval.
What challenges does Amgen face?
Biosimilar competition affects Prolia and Enbrel. Sales erosion is expected in 2026.
References
Amgen. (2026, April 30). Amgen reports first quarter 2026 financial results. https://www.amgen.com/newsroom/press-releases/2026/04/amgen-reports-first-quarter-2026-financial-results
